As the leader of the MILenARI project, Clínic-IDIBAPS stands at the forefront of academic CAR‑T innovation. The Barcelona team developed the first academic CAR‑T therapy authorized, now being scaled for international deployment.
As the leader of the MILenARI project, Clínic-IDIBAPS stands at the forefront of academic CAR‑T innovation. With a long track record in advanced therapies, the Barcelona team developed ARI‑0001, the first academic CAR‑T therapy authorized under Hospital Exemption in Europe, now being scaled for international deployment.
CAR-T therapy is an advanced immunotherapy that has revolutionized the treatment of certain hematological cancers. It consists of modifying the patient’s T lymphocytes to recognize and destroy tumor cells. Despite its potential, access to this therapy is limited due to high costs, the complexity of the process, and centralized production, which makes its implementation difficult in many countries.
Within MILenARI, Clínic-IDIBAPS coordinates the full project implementation, ensuring scientific excellence, ethical compliance, risk management, and effective communication across all partners. Their central technical mission focuses on scaling up the production of lentiviral vectors, the essential component for CAR‑T cell engineering. Through the establishment and validation of a large-scale production system, IDIBAPS will supply high‑quality vectors to all Mediterranean partner institutions.
In parallel, experts from this institution will lead intensive training programmes, transferring knowledge on CAR‑T manufacturing, quality control, and clinical management to teams in Lebanon, Jordan, and Italy. Their contribution is fundamental to support the decentralised implementation of point‑of‑care CAR‑T technologies across the region.
With their combined expertise, IDIBAPS and Hospital Clínic not only drive the scientific core of MILenARI, but also act as catalysts for the project’s ultimate objective: democratising access to innovative cancer therapies throughout the Mediterranean.
Last Update
24/02/2026
Next Med